drugset
drugset / Trial / NCT07371663

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

NCT07371663 ↗

Phase 1/2 Recruiting 266 enrolled Beijing Tide Pharmaceutical Co., Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with advanced solid tumors. The Phase II expansion study will assess the efficacy and safety of TCC1727 combined with benmelstobart /olaparib/topotecanin selected advanced solid tumor indications. The study pre-specifies three treatment combinations, with Combination 1 (TCC1727 + benmelstobart) being prioritized for initial evaluation. The decision to proceed with Combination 2 and Combination 3will be based on clinical data from Combination 1.

Timeline

Start
2025-12-03
Primary completion
2028-09-30
Completion
2029-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject TCC1727 Unknown 90 mg Oral
Subject TCC1727 Unknown 120 mg Oral
Subject TCC1727 Unknown 160 mg Oral
Background Benmelstobart Monoclonal antibody 1200 mg Intravenous

Indications

endometrial cancer gastric cancer melanoma non-small cell lung carcinoma